🔎 Trials Near Me

Domov › Rak dojke › Kentucky

Klinične študije za Rak dojke v Kentucky

24 študij za Rak dojke išče udeležence na lokacijah v Kentucky.

Mesta v Kentucky

Uradno besedilo študije (angleško)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
  • Commonwealth Cancer Center-Corbin, Corbin
  • Saint Elizabeth Healthcare Edgewood, Edgewood
  • in še 5
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • Baptist Health Lexington ( Site 0050), Lexington
  • Baptist Health Hamburg ( Site 0071), Lexington
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07060807

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053), Edgewood
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06312176

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • Saint Elizabeth Medical Center Edgewood, Edgewood
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

  • University of Kentucky Chandler Medical Center, Lexington
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 22. sep. 2026 · NCT07287098

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  • University Medical Center, Inc. DBA University of Louisville Hospital/James Graham Brown Cancer Center, Louisville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07173751

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • UofL Health Brown Cancer Center, Louisville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT06492616

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  • Research Site, Edgewood
  • Research Site, Louisville
Vključevanje udeležencevFaza 3
Starost 18–130 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT07647328

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

  • University of Kentucky-Lexington, Lexington
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT05846789

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • Baptist Health Lexington, Lexington
  • Baptist Health Hamburg, Lexington
  • University of Kentucky - Markey Cancer Center, Lexington
  • in še 2
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • King's Daughter's Medical Center, Ashland
  • CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
  • Baptist Health Corbin, Corbin
  • in še 13
Vključevanje udeležencevFaza 3
Starost 18–60 · Ženske · Posodobljeno 2. sep. 2026 · NCT05879926

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • St. Elizabeth Healthcare, Edgewood
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT06774963

E-Mindfulness Approaches for Living After Breast Cancer

  • King's Daughter's Medical Center, Ashland
  • CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
  • CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18–50 · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT06748222

EXoPERT EMERALD Clinical Study

  • Lexington VA Healthcare System, Lexington
  • KCTL, Louisville
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 45 in več · Vsi spoli · Posodobljeno 1. jul. 2026 · NCT07186296

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Norton Cancer Institute, Louisville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT05696626

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • UK Markey Cancer Center, Lexington
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 11. jun. 2026 · NCT05283330

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  • Mercy Health-Paducah Cancer Center, Paducah
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. maj 2026 · NCT06757634

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  • Saint Joseph Hospital, Lexington
  • Saint Joseph Radiation Oncology Resource Center, Lexington
  • Saint Joseph Hospital East, Lexington
  • in še 1
Vključevanje udeležencevFaza 3
Starost 50–70 · Vsi spoli · Posodobljeno 23. apr. 2026 · NCT04852887

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Flaget Memorial Hospital, Bardstown
  • Saint Joseph Hospital East, Lexington
  • Saint Joseph London, London
  • in še 2
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06418204

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • University of Kentucky Markey Cancer Center, Lexington
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 13. feb. 2026 · NCT06778863

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

  • St. Elizabeth Edgewood Hospital, Edgewood
  • Norton Cancer Institute - Downtown, Louisville
  • Baptist Health Louisville, Louisville
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 20. jan. 2026 · NCT06401421

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Baptist Corbin, Corbin
  • Baptist Hardin, Elizabethtown
  • Baptist Lexington, Lexington
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40 in več · Vsi spoli · Posodobljeno 20. jan. 2026 · NCT05366881

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • Saint Joseph Hospital East, Lexington
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 8. okt. 2025 · NCT03418961

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

  • James Graham Brown Cancer Center, Louisville
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 20. feb. 2025 · NCT04990921

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.